Doliver Advisors LP Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Doliver Advisors LP increased its holdings in Thermo Fisher Scientific by 28.7% during Q2, bringing their total shares to 3,742, valued at approximately $1.5 million.
• Analysts generally maintain a "Moderate Buy" consensus on Thermo Fisher Scientific, with target prices ranging from $480.00 to $561.00.
• The company announced a dividend of $0.43 per share to be paid on October 15th, representing a 0.4% dividend yield.

Doliver Advisors LP lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 28.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,742 shares of the medical research company's stock after buying an additional 835 shares during the period. Doliver Advisors LP's holdings in Thermo Fisher Scientific were worth $1,517,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $25,000. CBIZ Investment Advisory Services LLC increased its position in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after buying an additional 33 shares in the last quarter. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $30,000. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific in the first quarter worth about $30,000. Finally, Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $31,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on TMO shares. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. HSBC reaffirmed a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI cut their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $592.24.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $479.48 on Friday. The company has a market capitalization of $181.06 billion, a P/E ratio of 27.73, a P/E/G ratio of 2.62 and a beta of 0.75. The business's 50-day moving average is $466.86 and its two-hundred day moving average is $451.65. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.